Abstract:Abstract Funding Acknowledgements Type of funding sources: None. Background Pulmonary vein isolation (PVI) is an established therapy for symptomatic atrial fibrillation (AF) and the cryoballoon (CB) has become a standard tool for PVI. But the technology is limited in certain ways. The novel multi-electrode balloon catheter promises the advantages of a balloon technology in combination with 3D-mapping and more flexible energy delivery. Purpose There is very limited data available regarding the safety and efficacy of the Heliostar™ RF-balloon. We therefore aimed to assess procedure characteristics, efficacy, and safety in direct comparison with the established CB. Methods All patients undergoing PVI using the Heliostar™ between September 2021 and March 2022 were included in this single center registry. Procedural data and outcome were assessed and compared with data from consecutive patients undergoing initial PVI for paroxysmal AF with the CB from our specifically designed database. Results A total of 251 consecutive patients (63±13 years, 54% male) were included. Of those 28 patients undergoing RF-balloon and 223 patients CB PVI. Baseline parameters did not differ between groups. Acute PVI was achieved in all patients using CB and in 26/28 patients (93%) with the RF-balloon. In 2/28 patients an additional single tip catheter was needed. A mean of 11.2±4.9 RF-applications with 2.8±1.4 applications per vein (LSPV 3.2±2.9, LIPV 2.6±2.5, RSPV 2.8±2.0 and RIPV 1.8±0.8) were necessary to achieve a durable isolation. Using the CB, significantly less applications (5.9±2.2;p=<0.001) were needed. While procedure duration (111±30min. vs. 70min.;p=<0.001) and fluoroscopy time (17.2±6.3min. vs. 11.5±4.8min.;p=<0.001) were longer in the Heliostar™ group, time to isolation was significantly shorter using the RF-balloon: LSPV 23.5±12.3 sec. vs. 54.6±38.3 sec. (p=<0.001); LIPV 18.6±10.4 sec. vs. 61.2±46.5 sec. (p=0.002); RSPV 17.4±10.9 sec. vs. 62.5±53.9 sec. (p=<0.001); RIPV 16.1±9.3 sec. vs. 59.3±35.9 sec. (p=<0.001). One pericardial effusion occurred in the Heliostar™ group due to complicated transseptal access. During CB PVI in 4/223 patients (1.8%) a phrenic nerve palsy was observed, which resolved in all patients within 12-month. After 12-month 80% of patients in the Heliostar™ and 79% of patients in the CB group (p=0.9) were free from atrial arrhythmias. Conclusion The novel multi-electrode RF-balloon has shown to be safe and effective with good long-term results. In comparison with the CB, time to isolation was significantly shorter but procedure durations were longer and fluoroscopy exposition was higher using the first generation Heliostar™ without LassostarNav®. This can be attributed to the learning curve applying a new ablation system and the necessity for separate 3D map preparation. More experience is needed in the future, especially with the new generation Heliostar™ to determine the real benefits.

A novel saline-based occlusion tool allows for dye-less cryoballoon-based pulmonary vein isolation and fluoroscopy reduction

Cryoballoon Ablation of Atrial Fibrillation Without Demonstration of Pulmonary Vein Occlusion—The Simplify Cryo Study

Feasibility study of cryoballoon ablation for atrial fibrillation with KODEX-EPD: a single center experience

Intraprocedural Endpoints To Predict Durable Pulmonary Vein Isolation: A Randomized Trial Of Four Post-Ablation Techniques

Novel occlusion tool software for pulmonary vein occlusion verification in atrial fibrillation cryoballoon ablation

Occlusion tool software for pulmonary vein occlusion verification in atrial fibrillation cryoballoon ablation

Performance of Two Tools for Pulmonary Vein Occlusion Assessment with a Novel Navigation System in Cryoballoon Ablation Procedure

A Simplified Approach to Pulmonary Vein Visualization during Cryoballoon Ablation of Atrial Fibrillation

Reducing radiation exposure in second-generation cryoballoon ablation without compromising clinical outcome

P1055Reduction of radiation exposure using an optimized fluoroscopy protocol in cryoballoon ablation does not compromise clinical outcome

Balloon technologies for pulmonary vein isolation—12-month outcome and comparison of the novel radiofrequency balloon with the cryoballoon in patients with paroxysmal atrial fibrillation

Pulsed Field Versus Cryoballoon Pulmonary Vein Isolation for Atrial Fibrillation: Efficacy, Safety, and Long-Term Follow-Up in a 400-Patient Cohort

One‐year outcomes of pulmonary vein isolation with a novel cryoballoon: Primary results of the FROZEN AF trial

Comparison of Arctic Front Advance Pro and POLARx cryoballoons for ablation therapy of atrial fibrillation: an intraprocedural analysis

A Tailored Ablation Protocol

Cryoballoon ablation without use of contrast for the treatment of paroxysmal atrial fibrillation

Efficacy and safety of pulmonary vein isolation with pulsed field ablation vs. novel cryoballoon ablation system for atrial fibrillation

Randomised clinical trial of cryoballoon versus irrigated radio frequency catheter ablation for atrial fibrillation—the effect of double short versus standard exposure cryoablation duration during pulmonary vein isolation (CIRCA-DOSE): methods and rationale

In vivo safety and pulmonary vein isolation performance of a new cryoballoon for the treatment of atrial fibrillation

Pulmonary vein isolation using a single size cryoballoon chosen according to transesophageal echocardiography information

Balloon technologies for pulmonary vein isolation - long-term follow-up and comparison of the novel radiofrequency balloon with the cryoballoon in patients with paroxysmal atrial fibrillation